Le Lézard
Classified in: Health, Science and technology, Business

Samsung BioLogics named a Fortune Future 50 company


- Boston Consulting Group and Fortune examined 1,100 publicly traded companies in 12 months
- Alphabet, Netflix, Alibaba Group Holdings were also listed in 'Fortune Future 50'
- Continue to satisfy not only customers but also patients through innovation in health care

INCHEON, South Korea, Oct. 18, 2018 /PRNewswire/ -- Samsung BioLogics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, announced today that it has been ranked on Fortune's Future 50 list of companies best positioned for strong future growth and breakout growth.

The Fortune, in partnership with Boston Consulting Group, crated 'Future 50' in 2017 and ranked 50 global companies with the best prospects for long-term growth.

The result is a composite of scores in four dimensions: Strategy, Technology and Investments, People, and Structure.

Alphabet, Netflix, Alibaba Group Holdings were also listed in 'Fortune Future 50' along with Samsung BioLogics.

Dr. T.H Kim, the president and CEO of Samsung BioLogics, said, "Positioned on 'Fortune Future 50' proves Samsung BioLogics' growth potential once again just in 7 years," and he added, "Samsung BioLogics will continue to make the full efforts to grow into a world leading biopharmaceutical drug development and manufacturing company that can help not only our customers but also our patients through continuous innovation and global market development."  

On the other hand, Samsung BioLogics' Plant 3 became cGMP ready in October 1st, 2018. Although the company is only seven years old, it became the world's largest CMO with total bioreactor capacity of 362,000 liters in Plant 1, 2, and 3.

In addition, Samsung BioLogics has secured CDMO contracts with 24 companies for 33 products and received 19 global manufacturing approvals as of the end of September.

SOURCE Samsung BioLogics Co., Ltd.


These press releases may also interest you

at 17:21
CHEMISTREE DEBENTUREHOLDERS APPROVE DEBT RESTRUCTURING
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Public Advisory - Fake Viagra seized from Jug City store in Scarborough, ON
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Receives Shareholder Approval for Delisting from TSX Venture Exchange
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...

at 17:00
L.A. Care and Blue Shield of California Promise Health Plans Celebrate New Community Resource Center in West Los Angeles, Highlight Five-Year Partnership Milestone
L.A. Care Health Plan and Blue Shield of California Promise Health Plan today held a grand opening ceremony for their Community Resource Center (CRC) in West Los Angeles (West L.A.) at 11173 W. Pico Blvd in Los Angeles....

at 16:55
Veterinary Management Groups (VMG) Launches Innovative Veterinary Economic Dashboard
Veterinary Management Groups (VMG) is proud to...

at 16:45
Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered...

More news about Health...


News published on and distributed by: